DFDA

Clopidogrel

Treatment for Lower Extremity Peripheral Arterial Disease

Typical Dosage: 75mg daily

Effectiveness
55%
Safety Score
72%
Clinical Trials
8
Participants
150K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
72
DangerousModerateSafe
Treatment Details
Dosage Range
75mg daily
Time to Effect
Days for antiplatelet effect, long-term for CV event reduction
Treatment Duration
Lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
40(Treat 40 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100(Treat 100 patients to see 1 additional serious adverse event)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100
Monitoring:$500
Side Effect Mgmt:$100
Total Annual:$700
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$20,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$286
Comparison vs Aspirin
Cost Difference
+$130/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Annual Societal Loss per Patient
$360
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$250/year
Time Cost
$120/year
Travel + wait time
Insurance Admin Cost
$240/year
Prior auth, claims
Rx Price
$100/year
Potential OTC Price
$50/year
Estimated if OTC available
Early Treatment Benefit
+0.08 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOW
Missed Diagnosis Risk
LOW
Clopidogrel Outcomes

for Lower Extremity Peripheral Arterial Disease

Efficacy Outcomes
Overall Effectiveness
+55%
Response Rate
+70%
Common Side Effects
Bleeding (non-major)
+5%
Major bleeding (e.g., GI hemorrhage)
+1%
Dyspepsia
+3%

Sources:

nih.gov
nih.gov
ahajournals.org

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
3 active trials recruiting for Clopidogrel in Lower Extremity Peripheral Arterial Disease

Evaluation of Platelet Aggregability in Patients With Previous Acute Myocardial Infarction or Concomitant Lower Extremity Peripheral Artery Disease

NCT06454045ACTIVE NOT RECRUITING
View Study
100 participants
OBSERVATIONAL
São Paulo, Brazil
Started: May 13, 2024

Vascular Trial Associated Registry Pilot

NCT07076082RECRUITINGPHASE4
View Study
350 participants
INTERVENTIONAL
Detroit, United States +1 more
Started: Oct 15, 2025

VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization

NCT06873321RECRUITINGPHASE4
View Study
100 participants
INTERVENTIONAL
Pernambuco, Brazil
Started: Feb 24, 2024
Completed Clinical Trials
2 completed trials for Clopidogrel in Lower Extremity Peripheral Arterial Disease

Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities

NCT02217501COMPLETEDPHASE3
View Study
159 participants
INTERVENTIONAL
Denver, United States +3 more
Started: Nov 1, 2015

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

NCT00687076COMPLETEDPHASE4
View Study
102 participants
INTERVENTIONAL
Houston, United States
Started: Apr 1, 2004